Search - tctmd.com

Displaying 421 - 440 of 477

Sort: Relevancy | Date

Presentation TCT 2012

Clopidogrel Is Still the Choice for Most!

Presenter: Shamir Mehta

October 24, 2012

Presentation TCT 2012

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Presenter: Hyeon-Cheol Gwon

October 24, 2012

Presentation TCT 2012

"Short- Versus Long-term Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Randomized Multicentre Trial." Circulation. 2012;125:2015-2026.

Presenter: Marco Valgimigli

October 24, 2012

Presentation TCT 2012

Ticagrelor Is the Right Choice: More Potent, Better Data!

Presenter: Dimitrios Alexopoulos

October 24, 2012

Presentation TCT 2012

The Longer the Better Is Still the Way to Go, at Least for Now!

Presenter: Laura Mauri

October 24, 2012

Presentation TCT 2012

Medical Therapy During Interhospital Transport: Fibrinolytic and/or Anticoagulant?

Presenter: Frans Van de Werf

October 24, 2012

Presentation TCT 2012

Longer Is Better Is Old School Thinking!

Presenter: Marco Valgimigli

October 24, 2012

Presentation TCT 2012

Cangrelor: CHAMPION PHOENIX Update

Presenter: Harvey White

October 24, 2012

Presentation TCT 2012

Bivalirudin: New Analyses, New Studies

Presenter: Gregg Stone

October 24, 2012

Presentation TCT 2012

A Representative Case with a Complication: Stent Thrombosis or Major Bleed?(2)

Presenter: David Erlinge

October 24, 2012

Presentation TCT 2012

A Representative Case with a Complication: Stent Thrombosis or Major Bleed?

Presenter: Wojciech Wojakowski

October 24, 2012

Presentation TCT 2012

TCT-56. Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding Events After Percutaneous Coronary Intervention

Presenter: Fabio Mangiacapra

October 23, 2012

Presentation TCT 2012

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

Presenter: Paul Gurbel

October 23, 2012

Presentation TCT 2012

TCT-52. Bivalirudin Reduces Cardiac Mortality in Patients with and Without Major Bleeding: The HORIZONS-AMI Trial

Presenter: Gregg Stone

October 23, 2012

Presentation TCT 2012

TCT-51. Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-eluting Stents: Insight from the Florence Left Main-PCI...

Presenter: Renato Valenti

October 23, 2012

$TCT-50. Influence of Age on Clinical Outcomes in Patients with NSTEMI Undergoing Treatment with Abciximab plus Unfractionated Heparin vs. Bivalirudin: Analysis of the ISAR...$

Presentation TCT 2012

TCT-50. Influence of Age on Clinical Outcomes in Patients with NSTEMI Undergoing Treatment with Abciximab plus Unfractionated Heparin vs. Bivalirudin: Analysis of the ISAR...

Presenter: Lamin King

October 23, 2012

Presentation TCT 2012

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

Presenter: Joseph Jakubowski

October 23, 2012

Presentation TCT 2012

TCT-55. Major Adverse Cardiac Events Associated with Discontinuation of Clopidogrel Treatment Within the First Year After Coronary Stent Implantation in Western Denmark

Presenter: Michael Maeng

October 23, 2012

News Conference News TCT 2012

PARADOX: Smoking Enhances Effect of Clopidogrel, Prasugrel Unaffected by Smoking Status

October 23, 2012

Presentation TCT 2012

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

Presenter: David Kandzari

October 22, 2012

Advertisement

Clopidogrel Is Still the Choice for Most!

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

"Short- Versus Long-term Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Randomized Multicentre Trial." Circulation. 2012;125:2015-2026.

Ticagrelor Is the Right Choice: More Potent, Better Data!

The Longer the Better Is Still the Way to Go, at Least for Now!

Medical Therapy During Interhospital Transport: Fibrinolytic and/or Anticoagulant?

Longer Is Better Is Old School Thinking!

Cangrelor: CHAMPION PHOENIX Update

Bivalirudin: New Analyses, New Studies

A Representative Case with a Complication: Stent Thrombosis or Major Bleed?(2)

A Representative Case with a Complication: Stent Thrombosis or Major Bleed?

TCT-56. Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding Events After Percutaneous Coronary Intervention

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

TCT-52. Bivalirudin Reduces Cardiac Mortality in Patients with and Without Major Bleeding: The HORIZONS-AMI Trial

TCT-51. Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-eluting Stents: Insight from the Florence Left Main-PCI...

TCT-50. Influence of Age on Clinical Outcomes in Patients with NSTEMI Undergoing Treatment with Abciximab plus Unfractionated Heparin vs. Bivalirudin: Analysis of the ISAR...

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

TCT-55. Major Adverse Cardiac Events Associated with Discontinuation of Clopidogrel Treatment Within the First Year After Coronary Stent Implantation in Western Denmark

PARADOX: Smoking Enhances Effect of Clopidogrel, Prasugrel Unaffected by Smoking Status

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content